Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs TeraWulf Inc (WULF) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
TeraWulf IncTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs TeraWulf Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while TeraWulf Inc trades at $17.16 (market cap $8.35B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.5× TeraWulf Inc's market cap, and TeraWulf Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.

ALNYWULF
Market Cap
$29.60B$8.35B
Sector
HealthTechnology
52-Week High
$491.22$28.98
52-Week Low
$205.48$5.24
Enterprise Value
$27.56B$10.97B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.

Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.

TeraWulf Inc

WULF trades at $17.04, up 5.19% on the day amid a broader neocloud infrastructure rally. The stock shows bearish technical signals with 17 sell signals versus 2 buys, while fundamentals reveal significant challenges with a -1,179.94% net income margin and consistent earnings misses. Recent Q2 2026 results showed a $0.37 per share loss versus $0.20 expected, though revenue beat estimates. The company is expanding its high-performance computing capacity with 102 MW operational and 336 MW under construction, supported by a major Anthropic leasing agreement.

Despite unanimous analyst buy ratings and a $38 consensus price target representing 123% upside, WULF faces substantial execution risks and profitability concerns. The transition to AI infrastructure offers long-term potential, but near-term losses and high capital requirements create volatility. Investors should weigh the significant growth opportunity against persistent negative cash flow and competitive pressures in the evolving data center market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About TeraWulf Inc

TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.

Read more on WULF